A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 20 Jul 2017 Results of a post-hoc analysis assessing the maintenance of improvement on Severe Impairment Battery (SIB) performance among memantine ER-treated participants presented at the Alzheimer's Association International Conference 2017
    • 28 Apr 2017 Results of exploratory post-hoc analysis assessing effects of extended-release memantine across multiple outcome measures in patients with Alzheimers disease receiving donepezil, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 21 Apr 2016 Results of an exploratory post hoc analysis (n=593) presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top